.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,710,066

« Back to Dashboard

Claims for Patent: 6,710,066

Title: Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
Abstract:Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
Inventor(s): Kennedy; James C. (Kingston, CA), Pottier; Roy H. (Kingston, CA)
Assignee: Queen's University at Kingston (Kingston, CA)
Application Number:09/816,329
Patent Claims: 1. A method for treating in a human patient a non-malignant hyperproliferative skin lesion that preferentially accumulates a photoactivatable porphyrin, comprising administering to said human patient in need thereof an effective amount of a precursor of protoporphyrin IX thereby accumulating therapeutic levels of said protoporphyrin IX, and thereafter exposing said skin lesion to light capable of photoactivating said protoporphyrin IX.

2. The method of claim 1 wherein said precursor of protoporphyrin IX is administered topically.

3. A method for detecting in a human patient a non-malignant, hyperproliferative skin lesion that preferentially accumulates a photoactivatable porphyrin, comprising administering to said human patient in need thereof an effective amount of a precursor of protoporphyrin IX thereby accumulating detectable levels of said protoporphyrin IX, and thereafter exposing said skin lesion to light capable of photoactivating said protoporphyrin IX.

4. The method of claim 3 wherein said precursor of protoporphyrin IX is administered topically.

5. The method of claim 1 wherein said precursor is 5-aminolevulinic acid.

6. The method of claim 3 wherein said precursor is 5-aminolevulinic acid.

7. A method of treating a non-malignant, hyperproliferative skin lesion in a human patient in which protoporphyrin IX is produced from 5-aminolevulinic acid, comprising exposing said skin lesion in said human patient to a wavelength of light within the photoactivating spectrum of protoporphyrin IX.

8. A method of treating a non-malignant, hyperproliferative skin lesion in a human patient in which protoporphyrin IX is produced from 5-aminolevulinic acid, comprising exposing said skin lesion in said human patient to a wavelength of light within the photoactivating spectrum of protoporphyrin IX, wherein said light is generated using an artificial light source.

9. A method according to claim 7, wherein said light is only within the absorption spectrum of protoporphyrin IX.

10. A method according to claim 7, wherein said wavelength of light is limited to the group of wavelengths consisting of 350 to 700 nanometers.

11. A method according to claim 7, wherein the photoactivating light is limited to the red and blue regions of the spectrum.

12. A method of treating a non-malignant, hyperproliferative skin lesion, comprising (a) administering to a human patient a compound that induces accumulation of protoporphyrin IX in said skin lesion and then (b) exposing said skin lesion to a wavelength of light within the photoactivating spectrum of protoporphyrin IX.

13. A method according to claim 12, wherein said wavelength of light is generated using an artificial light source.

14. A method according to claim 12, wherein said wavelength of light is limited to the group of wavelengths consisting of 350 to 700 nanometers.

15. A method according to claim 12, wherein the photoactivating light is limited to the red and blue regions of the spectrum.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc